Trial Profile

Pilot Trial of 18F-BMS-986229 PET in Esophagogastric Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 18F BMS 986229 (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

06 Mar 2024 Status changed from active, no longer recruiting to completed.
20 Jan 2024 Results of Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using 18F-BMS-986229 PET, presented at the 2024 Gastrointestinal Cancers Symposium
02 Jul 2022 Results presented at the 24th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com